Hundreds of reactions and multiple deaths linked to weight-loss jabs
Data from the medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), shows that since the drugs were licensed there have been hundreds of cases of acute and chronic pancreatitis among people taking GLP-1 medicines.
This includes:
READ MORE: Government says stock up on nine emergency items as war risk increases
READ MORE: Emergency alert to be sent to every UK mobile phone
181 reported cases of acute and chronic pancreatitis linked to tirzepatide – the active ingredient for Mounjaro. Five people died.
116 reported reactions of this kind linked to liraglutide, one of which was fatal.
113 cases of acute and chronic pancreatitis linked to semaglutide – the active ingredient for Ozempic and Wegovy. One person died.
101 reported reactions of this kind linked to exenatide, three people died.
52 reported reactions of this sort linked to dulaglutide and 11 reported reactions lixisenatide. No fatalities were linked to either drug.
These cases are not confirmed as being caused by the medicines, but the person who reported them suspected they may be. Nonetheless, Yellow Card Biobank project, launched by the MHRA and Genomics England, will see researchers examine whether cases of pancreatitis linked to GLP-1 drugs may be influenced by peoples genetic makeup.
The MHRA is calling for people who are taking GLP-1 medicine who have been admitted to hospital due to acute pancreatitis to submit a report to its Yellow Card scheme. When a Yellow Card report is received, the MHRA will contact patients to ask if they would be willing to take part in the study.
Patients will be asked to submit more information and a saliva sample which will be assessed to explore whether some people are at a higher risk of acute pancreatitis when taking these medicines due to their genes. GLP-1 agonists can lower blood sugar levels in people living with type 2 diabetes and can also be prescribed to support some people with weight loss.
Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs. Health officials have suggested that they can help to turn the tide on obesity, but have stressed they are not a silver bullet and do come with side effects.
Most side effects linked to the jabs are gastrointestinal including nausea, constipation and diarrhoea. And the medical regulator recently warned that Mounjaro may make the oral contraceptive pill less effective in some patients.
Dr Alison Cave, MHRA's chief safety officer, said: 'Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing, it is predicted that adverse drug reactions could cost the NHS more than £2.2 billion a year in hospital stays alone.
'Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions – enabling patients across the UK to receive the safest medicine for them, based on their genetic makeup. To help us help you, we're asking anyone who has been hospitalised with acute pancreatitis while taking a GLP-1 medicine to report this to us via our Yellow Card scheme.
'Even if you don't meet the criteria for this phase of the Biobank study, information about your reaction to a medication is always extremely valuable in helping to improve patient safety.'
Professor Matt Brown, chief scientific officer of Genomics England, said: 'GLP-1 medicines like Ozempic and Wegovy have been making headlines, but like all medicines there can be a risk of serious side effects. We believe there is real potential to minimise these with many adverse reactions having a genetic cause.
'This next step in our partnership with the MHRA will generate data and evidence for safer and more effective treatment through more personalised approaches to prescription, supporting a shift towards an increasingly prevention-focused healthcare system.'
Both Eli Lilly, which makes Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy, have been approached for comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
37 minutes ago
- Associated Press
Wegovy® (semaglutide 2.4mg) by Novo Nordisk is now Available in Singapore for Weight Management
SINGAPORE - Media OutReach Newswire - 12 July 2025 - A significant advancement in weight management has arrived for Singaporeans. Novo Nordisk, a global healthcare company focused on defeating serious chronic diseases, has announced the availability of Wegovy® (semaglutide 2.4mg) in Singapore. Wegovy® (semaglutide 2.4mg) is a once-weekly injectable treatment indicated for chronic weight management in adults and adolescents (aged 12 and above) living with obesity (BMI ≥30 kg/m²), or who are overweight (BMI ≥27 kg/m² to <30 kg/m²) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia1. It is used alongside a reduced-calorie diet and increased physical activity, supporting Singapore's efforts to improve population health. The treatment works by addressing one of the underlying biological drivers of obesity. Wegovy® (semaglutide 2.4mg) is a GLP-1 receptor agonist with 94% similarity to the body's natural GLP-1 hormone. It activates receptors involved in appetite regulation, helping individuals feel full sooner and reduce food intake1. This mechanism supports weight loss when combined with sustainable lifestyle changes. The availability of Wegovy® (semaglutide 2.4mg) comes as obesity continues to pose a significant health burden in Singapore. An estimated 600,000 adults are currently living with obesity2-4, a condition associated with more than 200 health complications5. Despite its prevalence and medical complexity, obesity remains heavily stigmatised—often misunderstood as merely the result of poor personal choices. Individuals living with obesity frequently face discrimination and mental health challenges which further isolate them. This misplaced blame, rather than targeting the disease itself, creates barriers to and slows the advancement of effective obesity treatment. Recognised by World Health Organization as a chronic disease6, obesity requires compassionate evidence-based care. The launch of Wegovy® (semaglutide 2.4mg) in Singapore provides a new treatment option for weight management available through private prescription. Dr Abel Soh, Abel Soh Diabetes, Thyroid and Endocrine Clinic and Chairperson for Endocrine and Metabolic Society of Singapore (EMSS) stated, 'Obesity is not simply the result of lifestyle choices — it is a medically recognised chronic disease influenced by a complex interplay of genetics, hormones, and environment. In my clinical practice, I see firsthand how many individuals blame themselves when in fact, their biology is often working against them. It's time we shift the conversation from blame to support in the management of individuals with obesity' Lifestyle factors in Singapore further contribute to the challenge. In Singapore's demanding work culture—where full-time employees work an average of 44.6 hours per week7, with time constraints and fatigue frequently cited as barriers to maintaining regular physical activity. These circumstances underscore the importance of comprehensive treatment strategies that facilitate the adoption of healthier lifestyles, including increased physical activity and a reduced-calorie diet, as integral components of long-term weight management. Mr Vincent Siow, General Manager, Novo Nordisk Singapore, said 'With treatments like Wegovy® (semaglutide 2.4mg) now available in Singapore, we have an opportunity to provide healthcare professionals with more evidence-based options to support their patients in regaining control of their health and improving long-term outcomes.' References: Wegovy Singapore Prescribing Information, February 2025Cuciureanu M, Caratașu CC, Gabrielian L, Frăsinariu OE, Checheriță LE, Trandafir LM, Stanciu GD, Szilagyi A, Pogonea I, Bordeianu G, Soroceanu RP, Andrițoiu CV, Anghel MM, Munteanu D, Cernescu IT, Tamba BI. 360-Degree Perspectives on Obesity. Medicina (Kaunas). 2023 Jun 9;59(6):1119. doi: 10.3390/medicina59061119. PMID: 37374323; PMCID: Obesity. Retrieved from World Obesity. Retrieved from I. Kahan, MD, MPH. Practical Strategies for Engaging Individuals With Obesity in Primary Care. Mayo Clin Proc. 2018;93(3):351-359 2. CDC, Cancers Associated with Overweight and Obesity Makeup 40 percent of Cancers Diagnosed in the United States. Available at Health Organization. (2024). Obesity and As accessed on 22nd May J, Rebello SA, Sargent GM, Kelly M, Banwell C. Hard work, long hours, and Singaporean young adults' health. A qualitative study. Frontiers in Public Health. 2023; 11. Hashtag: #NovoNordisk #Wegovy The issuer is solely responsible for the content of this announcement. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs around 77,400 people in 80 countries and markets its products in around 170 countries. In Singapore, Novo Nordisk has been present since 1997 and has approximately 100 employees. For more information, visit
CNN
an hour ago
- CNN
See inside the UK's first safer drug consumption facility
It's been six months since the UK's first and only drug consumption facility opened in Glasgow, Scotland. Designed as a 'safe space' to inject illegally-bought Class A drugs with medical supervision, it's located in a part of the city with a high amount of public drug use. Funded by the Scottish government, the aim is to help reduce fatal overdoses in the country - which has the highest rate of drug-related deaths in Europe, according to Scottish health officials. It follows similar incentives in other European cities, but the idea still remains controversial. CNN visited the clinic to see how it works.
Yahoo
an hour ago
- Yahoo
Relief in Brixham as South West Water boss retires
South West Water (SWW) boss Susan Davy's retirement has come as a welcome relief for one customer. Brixham resident Louise Harcarova-Geary fell ill during the cryptosporidium outbreak along with her young daughter in 2024. The outbreak, which left 143 people ill and led to four hospitalisations, was traced to a contaminated reservoir. Ms Davy's retirement was a "good thing, because there might be some change from this", said Ms Harcarova-Geary. Pennon Group, which owns SWW, praised her leadership, with chairman David Sproul saying she navigated the group "through some challenging external headwinds to emerge stronger and more resilient". Ms Harcarova-Geary, who still relies on bottled water a year after the outbreak, said she had lost trust in the company's supply. "Hopefully funds can be distributed properly to make sure our water integration system is properly maintained going forward," she said. Ms Davy, who had been with SWW's parent company Pennon Group for nearly two decades, faced mounting criticism for her handling of the crisis. Just a day before her retirement was announced, water regulator Ofwat revealed a £24m enforcement package against SWW, citing failings in how the company managed its network. Cryptosporidium outbreak in Brixham: Contaminated drinking water led to 143 confirmed illnesses and four hospitalisations in 2024 Regulatory action by Ofwat: Ofwat found failings in South West Water's management of wastewater treatment and sewer networks. A £24m enforcement package was introduced to avoid a £19m fine Environmental and pollution concerns: In June, one of SWW's treatment works was the source of pollution that killed thousands of fish in a Cornish river Repeated storm overflow incidents In April a burst water main in Plymouth left hundreds of homes and businesses without water for several days In a statement, Pennon Group praised Ms Davy's leadership, highlighting her role in acquiring three other water companies and overseeing a £4.2bn sale of waste firm Viridor. The company also noted her announcement of a record £3.2bn capital investment programme over the next five years. Pennon's board will conduct a formal search for a successor, during which time Ms Davy will continue to helm the company, it said in a statement. Details of Ms Davy's retirement compensation will be published on the company's website, it said. She will be treated as a "good leaver" under the board's remuneration policy. Ms Davy said: "Running a water company is always interesting, often challenging, but totally fulfilling "I have enjoyed taking responsibility for the provision of a sustainable service to millions of homes." Follow BBC Cornwall on X, Facebook and Instagram. Follow BBC Devon on X, Facebook and Instagram. Send your story ideas to spotlight@ South West Water boss Susan Davy to retire Enforcement action of £24m for water firm failures Watch: South West Water boss on bills and spills South West Water
